Identification of novel splice variants in horn cancer by RNA-Seq analysis in Zebu cattle

Genomics

Volumn 101, Issue 1, 2013, Pages 57-63

  Patel, Amrutlal K ^a   Bhatt, Vaibhav D ^a   Tripathi, Ajai K ^a   Sajnani, Manisha R ^a   Jakhesara, Subhash J ^a   Koringa, Prakash G ^a   Joshi, Chaitanya G ^a  

^a Chhattisgarh Kamdhenu Vishwa Vidyalaya   (India)

Author keywords

Alternative splicing; BLAT; Frame shift; GT AG rule; Horn cancer; RT PCR; RT qPCR; Transcriptome sequencing

Indexed keywords

TRANSCRIPTOME;

ALTERNATIVE RNA SPLICING; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATTLE DISEASE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC VARIABILITY; HORN CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEQUENCE ANALYSIS;

ALTERNATIVE SPLICING; ANIMALS; CARCINOMA, SQUAMOUS CELL; CATTLE; CATTLE DISEASES; HORNS; NEOPLASMS; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME;

BOS INDICUS;

EID: 84871675546     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2012.10.001     Document Type: Article

References (32)

1. Singh S.P., Batra M., Singh G.K. Important aspects of horn cancer. Cow 2005, 32-34.
2. Joshi B.P., Soni P.B., Fefar D.T., Ghodasara D.J., Prajapati K.S. Epidemiological & pathological aspects of horn cancer in cattle of Gujarat. Indian J. Field Vet. 2009, 5:65-67.
3. Tripathi A.K., et al. A preliminary sketch of horn cancer transcriptome in Indian zebu cattle. Gene 2012, 493:124-131.
4. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64:7647-7654.
5. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010, 24:2343-2364.
6. Tazi J., Bakkour N., Stamm S. Alternative splicing and disease. Biochim. Biophys. Acta 2009, 1792:14-26.
7. Ritchie W., Granjeaud S., Puthier D., Gautheret D. Entropy measures quantify global splicing disorders in cancer. PLoS Comput. Biol. 2008, 4:e1000011.
8. Tanko Q., Franklin B., Lynch H., Knezetic J. A hMLH1 genomic mutation and associated novel mRNA defects in a hereditary non-polyposis colorectal cancer family. Mutat. Res. 2002, 503:37-42.
9. Klinck R., et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res. 2008, 68:657-663.
10. Hoffman J.D., Hallam S.E., Venne V.L., Lyon E., Ward K. Implications of a novel cryptic splice site in the BRCA1 gene. Am. J. Med. Genet. 1998, 80:140-144.
11. Lopez-Bigas N., Audit B., Ouzounis C., Parra G., Guigo R. Are splicing mutations the most frequent cause of hereditary disease?. FEBS Lett. 2005, 579:1900-1903.
12. Xing Y., Lee C. Alternative splicing and RNA selection pressure-evolutionary consequences for eukaryotic genomes. Nat. Rev. Genet. 2006, 7:499-509.
13. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72:291-336.
14. Caceres J.F., Kornblihtt A.R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 2002, 18:186-193.
15. Sultan M., et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321:956-960.
16. Sahara S., Aoto M., Eguchi Y., Imamoto N., Yoneda Y., Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 1999, 401:168-173.
17. Jang S.W., et al. Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. Cancer Res. 2008, 68:4559-4570.
18. Qin L., et al. Steroid receptor coactivator-1 upregulates integrin alpha expression to promote breast cancer cell adhesion and migration. Cancer Res. 2011, 71:1742-1751.
19. Man Y.G., Schwartz A., Levine P.H., Teal C., Berg P.E. BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness. Cancer Biomark. 2009, 5:9-17.
20. Yu M., Wan Y., Zou Q. Prognostic significance of BP1 mRNA expression level in patients with non-small cell lung cancer. Clin. Biochem. 2008, 41:824-830.
21. Ide Y., et al. Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem. Biophys. Res. Commun. 2006, 341:478-482.
22. Kotaskova J., et al. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J. Mol. Diagn. 2010, 12:328-334.
23. Dimberg J., Hugander A., Hall-Karlsson B.M., Sirsjo A. RFX-B, a MHC class II transcription factor, suppressed in human colorectal adenocarcinomas. Int. J. Mol. Med. 2002, 9:213-216.
24. Matsuyama R., et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int. J. Cancer 2006, 119:406-413.
25. Kleivi K., et al. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol. Cancer 2007, 6:2.
26. Eldridge A.G., Loktev A.V., Hansen D.V., Verschuren E.W., Reimann J.D., Jackson P.K. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1. Cell 2006, 124:367-380.
27. Giannone R.J., McDonald H.W., Hurst G.B., Shen R.F., Wang Y., Liu Y. The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1. PLoS One 2010, 5:e12407.
28. Bradshaw P.S., Stavropoulos D.J., Meyn M.S. Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage. Nat. Genet. 2005, 37:193-197.
29. Furuta J., Nobeyama Y., Umebayashi Y., Otsuka F., Kikuchi K., Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res. 2006, 66:6080-6086.
30. Camisaschi C., et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J. Immunol. 2010, 184:6545-6551.
31. Schwartz A.M., Man Y.G., Rezaei M.K., Simmens S.J., Berg P.E. BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia. Mod. Pathol. 2009, 22:1-6.
32. Fujita P.A., et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 2011, 39:D876-D882.